<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dorzolamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dorzolamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dorzolamide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9386" href="/d/html/9386.html" rel="external">see "Dorzolamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="12396" href="/d/html/12396.html" rel="external">see "Dorzolamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F162751"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trusopt [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866660"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Dorzolamide;</li>
<li>JAMP-Dorzolamide;</li>
<li>MED-Dorzolamide;</li>
<li>SANDOZ Dorzolamide;</li>
<li>Trusopt;</li>
<li>Trusopt (Preservative Free)</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058175"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Carbonic Anhydrase Inhibitor, Ophthalmic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462431"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb2a3b95-1c3e-4397-a60a-e7908e8247a1">Intraocular pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular pressure reduction:</b> GA ≥36 weeks and PNA ≥7 days: Ophthalmic: 1 drop to affected eye(s) 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16157797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16157797'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F162772"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb2a3b95-1c3e-4397-a60a-e7908e8247a1">Intraocular pressure reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular pressure reduction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i> Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop to affected eye(s) 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16157797','lexi-content-ref-30095601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16157797','lexi-content-ref-30095601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy (with latanoprost</i>): Limited data available: Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop to affected eye(s) 2 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30095601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30095601'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094199"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: All patients: Use is not recommended (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51094200"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doa drugH1Div" id="F162755"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9386" href="/d/html/9386.html" rel="external">see "Dorzolamide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6687a47-d77d-4bbc-a712-b27b54e1af1f">Ocular hypertension/glaucoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular hypertension/glaucoma (open-angle): Ophthalmic:</b> Instill 1 drop in the affected eye(s) 3 times daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991449"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Use is not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Dorzolamide and its metabolite (N-desethyl: less potent than parent) are excreted renally. Patients with renal impairment, particularly neonates and geriatric patients, should be monitored carefully for untoward effects due to reduced dorzolamide elimination.</p></div>
<div class="block doha drugH1Div" id="F50988757"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (have not been studied); use with caution.</p></div>
<div class="block adr drugH1Div" id="F162724"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Bitter taste (~25% following administration), nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Urolithiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Local ocular hypersensitivity reaction (~10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Nervous system: Fatigue, headache</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:2em;">Ocular: Burning sensation of eyes (~33%), eye discomfort (~33%), stinging of eyes (~33%), superficial punctate keratitis (10% to 15%), blurred vision (1% to 5%), conjunctivitis (1% to 5%), eyelid irritation (1% to 5%), eye redness (1% to 5%), lacrimation (1% to 5%), photophobia (1% to 5%), xerophthalmia (1% to 5%), iridocyclitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Angioedema, bronchospasm, choroidal detachment (following filtration procedures), contact dermatitis, crusting of eyelid, dizziness, dyspnea, epistaxis, myopia (transient), ocular pain, paresthesia, pruritus, Stevens-Johnson syndrome, throat irritation, toxic epidermal necrolysis, urticaria, xerostomia</p></div>
<div class="block coi drugH1Div" id="F162738"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to dorzolamide or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F162721"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Local ocular adverse effects (primarily conjunctivitis and lid reactions) were reported with chronic administration; many resolved upon discontinuation of drug therapy. Choroidal detachment has been reported after filtration procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: Dorzolamide is a sulfonamide; although administered ocularly, systemic absorption may occur and could result in hypersensitivity. Discontinue use if signs of hypersensitivity or a serious reaction occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Systemic absorption and adverse effects (similar to sulfonamides) including, blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias may occur with ophthalmic use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Corneal endothelium: Use with caution in patients with low endothelial cell counts; may be at increased risk of corneal edema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with severe renal impairment (CrCl &lt;30 mL/minute) (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should be used in combination with therapeutic interventions for the treatment of acute angle-closure glaucoma.</p></div>
<div class="block foc drugH1Div" id="F162732"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trusopt: 2% (10 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (10 mL)</p></div>
<div class="block geq drugH1Div" id="F162717"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F162740"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dorzolamide HCl Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $1.80 - $6.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866661"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trusopt: 2% (5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trusopt (Preservative Free): 2% (0.2 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (5 mL, 10 mL)</p></div>
<div class="block admp drugH1Div" id="F52612623"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Wash hands before use. Unscrew the cap by turning in the direction of the arrows on top of the cap. Pull lower eyelid down slightly to form a pocket for the eye drop and tilt head back; administer 1 drop. Apply gentle pressure to lacrimal sac immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>). Avoid contact of bottle tip with skin or eye; ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions. Some solutions contain benzalkonium chloride; remove contact lenses prior to administration and wait at least 15 minutes after instillation before reinserting soft contact lenses. If more than one topical ophthalmic drug is being used, separate administration by at least 5 minutes.</p></div>
<div class="block adm drugH1Div" id="F162735"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Ophthalmic: If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lens prior to administration and wait 15 minutes before reinserting. Avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Use eyelid closure or nasolacrimal occlusion when applying topical medications to reduce systemic absorption.</p></div>
<div class="block sts drugH1Div" id="F162749"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566575"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F162783"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F162726"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F13386400"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Because information related to dorzolamide use in pregnancy is limited, other agents may be preferred for the treatment of glaucoma in pregnant patients. Use of topical carbonic anhydrase inhibitors may be considered after the first trimester. In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Belkin 2020; Strelow 2020).</p></div>
<div class="block mopp drugH1Div" id="F53566576"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic ophthalmic exams, intraocular pressure.</p></div>
<div class="block pha drugH1Div" id="F162720"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversible inhibition of the enzyme carbonic anhydrase II and IV in the ciliary epithelium resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water to decrease production of aqueous humor to reduce intraocular pressure.</p></div>
<div class="block phk drugH1Div" id="F162737"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of action: 8 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Topical: Reaches systemic circulation where it accumulates in RBCs during chronic dosing as a result of binding to CA-II</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: In RBCs during chronic administration </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~33% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: To N-desethyl metabolite (less potent than parent drug) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal RBC half-life: 147 days; washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about 4 months </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as unchanged drug and metabolite, N-desethyl)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F162741"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apisopt | Trusopt | Xola</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Biodrop | Trusopt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dorlazept | Dorzo vision | Trusopt</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo dorzolamide | Trusamide | Trusopt</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide Mylan | Trusopt</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ozolamide</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dorzopt | Trusopt</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Andrum | Cloridrato de dorzolamida | Dorzal | Ocupress | Pert | Trusopt</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dorzo vision | Dorzolamid Teva | Trusopt</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Ozolamide | Proglau | Xola</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dorlenka | Dorzolamida | Dorzox | Glaucotensil | Trusopt</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dorzamid | Dorzodel | Dorzolam | Dorzopres | Dorzovision | Glaucotensil d | Trusopt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamid olikla | Oftidor | Trusopt | Vizidor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dimaz | Dorzo vision | Dorzolamid 1a pharma | Dorzolamid Actavis | Dorzolamid al | Dorzolamid dr mann | Dorzolamid Heumann | Dorzolamid hexal | Dorzolamid Hormosan | Dorzolamid micro labs | Dorzolamid ratiopharm | Dorzolamid sandoz | Dorzolamid stada | Dorzolamid stulln | Trusopt</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Glaucotensil d | Iripress | Trusopt</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dorlamida | Trusopt</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide | Trusopt | Vizidor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ozolamide | Ozolzmide | Queenzolamide | Xola</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamida | Dorzolamida aristo | Dorzolamida kern pharma | Dorzolamina Colirteva | Trusopt</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide HCL | Xola</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamid Actavis | Dorzolamid mylan | Dorzolamid ratiopharm | Dorzolamide teva | Trusopt</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide Actavis | Dorzolamide biogaran | Dorzolamide Chauvin | Dorzolamide Cristers | Dorzolamide eg | Dorzolamide Mylan | Dorzolamide teva | Trusopt</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide | Dorzolamide hydrochloride sandoz | Dorzolamide teva | Eydelto | Trusopt | Vizidor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dorolad | Optodrop | Trusopt</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dorzo | Trusopt</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dorvis | Dorzol | Trusopt</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dorzolep | Nodom | Trusopt</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide Actavis | Trusopt</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Arodor | Dortas | Dorzotry | Dorzox | Endor | Monosopt | Ocudor | Trusopt</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Dorzimid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dorzoclar | Dorzolamide | Dorzolamide Actavis | Dorzolamide doc generi | Dorzolamide Mylan | Dorzolamide ratiopharm | Dorzolamide tubilux pharma | Dorzostill | Trusopt | Zoliop</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apisopt | Daromed | Optodrop | Ozolamide | Trusopt</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Xola</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dozol | Trusopt</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Trusopt | Xola</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide bgr | Trusopt</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide Actavis | Dorzolamide portfarma | Nodofree | Nodom | Oftidor | Trusopt</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide Actavis | Dorzolamide portfarma | Nodom | Oftidor | Sakor | Trusopt</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Trusopt | Xola</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dorlenka | Dorzolamida | Drendor Tec | Iopzox ofteno | Pio Baj | Piobaj | Truglad | Trusopt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lamisopt | Trusopt</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dorsun</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide | Dorzolamide Actavis | Dorzolamide Cf | Dorzolamide Mylan | Dorzolamide Sandoz | Trusmono | Trusopt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamid ratiopharm | Trusopt</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Xola</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Atensor | Dorlip | Dorsof | Glaucotensil d | Mersolat D | Sefson | Trusomida | Trusopt | Unidorzo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adolamid | Dolopt | Dorzolamid stada | Dorzolamid Teva | Dorzolamide genoptim | Dorzostill | Dropzol | Nodom | Oftidor | Rozalin | Trusopt | Vizidor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamide HCL | Trusopt</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dorcil | Dorcilfree | Dorzolamida actavis | Dorzolamida Generis | Dorzolamida mylan | Dorzolamida Teva | Trusopt</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citol dorzo | Dorlamida</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Trusopt | Xola | Zolichek</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dorzopt</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dor antiglau eco | Dorzolamide nativ | Dorzolamide optic | Dorzolamide solopharm | Dorzolan solo | Dorzopt | Glaucopt | Trusopt</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trusopt | Xola | Zomidor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamid mylan | Dorzolamid orifarm | Dorzolamid sandoz | Dorzolamid stada | Trusopt</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Trusopt</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dorzolamid olikla | Dozotens | Trusopt</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lamisopt | Trusopt</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alzor | Trusopt</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dorzamed | Trusopt</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bolano | Dorzomide | Dorzostill | Trusopt</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dorsamed | Dorsol | Dorzoptic | Rezlod | Rozalin | Trusopt</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Atensor | Beyonas dorzo | Dorzomed | Glaucotensil d | Trusopt</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cofador | Dorzol | Dorzolamida | Glaucotensil d | Trusomida | Trusopt</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dorzopt | Glaucopress | Glaudor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Ophthalmology (AAO) PPP Glaucoma Panel, Hoskins Center for Quality Eye Care. Glaucoma summary benchmarks - 2019. https://www.aao.org/summary-benchmark-detail/glaucoma-summary-benchmarks-2019#PrimaryOpen-AngleGlaucoma(InitialEvaluation). Updated October 2019. Accessed December 23, 2019.</div>
</li>
<li>
<div class="reference">
                  Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM; American Glaucoma Society and the Canadian Glaucoma Society. A practical guide to the pregnant and breastfeeding patient with glaucoma. <i>Ophthalmol Glaucoma</i>. 2020;3(2):79-89. doi:10.1016/j.ogla.2019.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/32672600/pubmed" id="32672600" target="_blank">32672600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7720769">
<a name="7720769"></a>Biollaz J, Munafo A, Buclin T, et al, “Whole Blood Pharmacokinetics and Metabolic Affects of the Topical Carbonic Anhydrase Inhibitor Dorzolamide,” <i>Eur J Clin Pharmacol</i>, 1995, 47(5):455-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/7720769/pubmed" id="7720769" target="_blank">7720769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10448757">
<a name="10448757"></a>Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Nephrolithiasis with dorzolamide. <i>Arch Ophthalmol</i>. 1999;117(8):1087-1088. doi:10.1001/archopht.117.8.1087.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/10448757/pubmed" id="10448757" target="_blank">10448757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21075995">
<a name="21075995"></a>Douglass R, Heckman G. Drug-related taste disturbance: a contributing factor in geriatric syndromes. <i>Can Fam Physician</i>. 2010;56(11):1142-1147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/21075995/pubmed" id="21075995" target="_blank">21075995</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dorzolamide [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb, Inc; July 2016</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29333622">
<a name="29333622"></a>Hoffmanová I, Sánchez D. Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function. <i>Br J Clin Pharmacol</i>. 2018;84(4):796-799. doi:10.1111/bcp.13499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/29333622/pubmed" id="29333622" target="_blank">29333622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25897195">
<a name="25897195"></a>Lee SJ, Kim M. Allergic contact dermatitis caused by dorzolamide eyedrops. <i>Clin Ophthalmol</i>. 2015;9:575-577. doi:10.2147/OPTH.S74555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/25897195/pubmed" id="25897195" target="_blank">25897195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9029437">
<a name="9029437"></a>Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. <i>J Ocul Pharmacol Ther</i>. 1997;13(1):23-30. doi:10.1089/jop.1997.13.23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/9029437/pubmed" id="9029437" target="_blank">9029437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12881361">
<a name="12881361"></a>Morris S, Geh V, Nischal KK, Sahi S, Ahmed MA. Topical dorzolamide and metabolic acidosis in a neonate. <i>Br J Ophthalmol</i>. 2003;87(8):1052-1053. doi:10.1136/bjo.87.8.1052.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/12881361/pubmed" id="12881361" target="_blank">12881361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16157797">
<a name="16157797"></a>Ott EZ, Mills MD, Arango S, Getson AJ, Assaid CA, Adamsons IA. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. <i>Arch Ophthalmol</i>. 2005;123(9):1177-1186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/16157797/pubmed" id="16157797" target="_blank">16157797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30095601">
<a name="30095601"></a>Quaranta L, Biagioli E, Riva I, et al. The Glaucoma Italian Pediatric Study (GIPSy): 3-year results. <i>J Glaucoma</i>. 2018;27(10):856-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/30095601/pubmed" id="30095601" target="_blank">30095601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Strelow B, Fleischman D. Glaucoma in pregnancy: an update. <i>Curr Opin Ophthalmol</i>. 2020;31(2):114-122. doi:10.1097/ICU.0000000000000641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/31922978/pubmed" id="31922978" target="_blank">31922978</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Trusopt (dorzolamide) [prescribing information]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17305746">
<a name="17305746"></a>Turgut B, Türkçüoğlu P, Güler M, Akyol N, Celiker U, Demir T. Anosmia as an adverse effect of dorzolamid. <i>Acta Ophthalmol Scand</i>. 2007;85(2):228-229. doi:10.1111/j.1600-0420.2006.00857.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/17305746/pubmed" id="17305746" target="_blank">17305746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8216014">
<a name="8216014"></a>Wilkerson M, Cyrlin M, Lippa EA, et al, “Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active, Topical Carbonic Anhydrase Inhibitor,” <i>Arch Ophthalmol</i>, 1993, 111(10):1343-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/8216014/pubmed" id="8216014" target="_blank">8216014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs.<i> Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dorzolamide-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13250 Version 203.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
